Summary of FACS analyses of naive T-cell subsets
| Patients . | Diagnosis . | MG . | CD4-CD8 ratio (range) . | CD45RA+ cells, % CD3 . | CD3+CD45RA+ . | |
|---|---|---|---|---|---|---|
| CD4+ . | CD8+ . | |||||
| 1-9 | Thymoma | Yes | 2.6 (0.7-11.0)3-150 | 63.2 ± 17.4 | 31.0 ± 10.8 | 32.2 ± 16.73-150 |
| Control | No | 4.9 (2.0-8.3) | 57.1 ± 16.6 | 39.4 ± 16.1 | 14.5 ± 9.1 | |
| 10-22 | Thymoma | No | 2.6 (0.43-12.6)3-150 | 61.9 ± 25.4 | 25.4 ± 10.33-150 | 36.5 ± 18.93-150 |
| Control | No | 4.6 (1.9-9) | 51.2 ± 17.3 | 37.0 ± 15.7 | 14.0 ± 6.8 | |
| 23-35 | TFH | Yes | 2.3 (0.6-6.0)3-150 | 64.2 ± 15.6 | 37.3 ± 18.8 | 26.9 ± 10.2 |
| Control | No | 2.3 (1.0-4.3) | 76.0 ± 9.6 | 41.1 ± 10.6 | 34.9 ± 11.4 | |
| Patients . | Diagnosis . | MG . | CD4-CD8 ratio (range) . | CD45RA+ cells, % CD3 . | CD3+CD45RA+ . | |
|---|---|---|---|---|---|---|
| CD4+ . | CD8+ . | |||||
| 1-9 | Thymoma | Yes | 2.6 (0.7-11.0)3-150 | 63.2 ± 17.4 | 31.0 ± 10.8 | 32.2 ± 16.73-150 |
| Control | No | 4.9 (2.0-8.3) | 57.1 ± 16.6 | 39.4 ± 16.1 | 14.5 ± 9.1 | |
| 10-22 | Thymoma | No | 2.6 (0.43-12.6)3-150 | 61.9 ± 25.4 | 25.4 ± 10.33-150 | 36.5 ± 18.93-150 |
| Control | No | 4.6 (1.9-9) | 51.2 ± 17.3 | 37.0 ± 15.7 | 14.0 ± 6.8 | |
| 23-35 | TFH | Yes | 2.3 (0.6-6.0)3-150 | 64.2 ± 15.6 | 37.3 ± 18.8 | 26.9 ± 10.2 |
| Control | No | 2.3 (1.0-4.3) | 76.0 ± 9.6 | 41.1 ± 10.6 | 34.9 ± 11.4 | |
Data based on the peripheral blood of MG(+) and MG(−) thymoma patients and MG(+) patients with nonneoplastic thymuses (TFH) compared with the respective sex- and age-matched control cohort. For detailed graphical overview of data, see Figure 4.
Statistically significant alteration.